Wealth Effects LLC Decreases Stake in Autolus Therapeutics PLC Sponsored ADR $AUTL

Wealth Effects LLC lowered its position in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 62.8% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 13,500 shares of the company’s stock after selling 22,800 shares during the quarter. Wealth Effects LLC’s holdings in Autolus Therapeutics were worth $31,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in AUTL. Jane Street Group LLC acquired a new stake in Autolus Therapeutics during the 4th quarter worth about $26,000. Millennium Management LLC lifted its holdings in Autolus Therapeutics by 91.6% in the fourth quarter. Millennium Management LLC now owns 1,653,241 shares of the company’s stock valued at $3,885,000 after acquiring an additional 790,437 shares during the period. Two Sigma Investments LP boosted its position in Autolus Therapeutics by 23.8% in the 4th quarter. Two Sigma Investments LP now owns 906,767 shares of the company’s stock worth $2,131,000 after purchasing an additional 174,485 shares in the last quarter. Two Sigma Advisers LP grew its stake in shares of Autolus Therapeutics by 4.8% during the 4th quarter. Two Sigma Advisers LP now owns 333,400 shares of the company’s stock worth $783,000 after purchasing an additional 15,400 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of Autolus Therapeutics by 4.6% during the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock valued at $59,562,000 after purchasing an additional 1,125,454 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on AUTL. Needham & Company LLC restated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, July 21st. Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Wells Fargo & Company reduced their target price on Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, August 13th. Finally, William Blair reissued an “outperform” rating on shares of Autolus Therapeutics in a research note on Wednesday. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $9.12.

Autolus Therapeutics Price Performance

NASDAQ AUTL opened at $1.56 on Thursday. Autolus Therapeutics PLC Sponsored ADR has a 12 month low of $1.11 and a 12 month high of $5.00. The stock has a market capitalization of $415.18 million, a P/E ratio of -1.86 and a beta of 1.87. The firm’s 50-day moving average is $1.87 and its two-hundred day moving average is $1.80.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.06. The company had revenue of $13.50 million during the quarter, compared to analyst estimates of $12.92 million. As a group, analysts anticipate that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.